In the CHRYSALIS-2 study, amivantamab plus lazertinib showed a 52% overall response rate in patients with atypical EGFR-mutated advanced NSCLC. The combination treatment led to a median progression-free survival of 11.1 months. The safety profile was consistent with previous studies, with no new safety signals observed.
Study
|
Open-label, phase I/Ib, multicenter study [Cohort C of CHRYSALIS-2] |
| Advanced or metastatic NSCLC with atypical activating EGFR mutations (including but not limited to S768I, L861Q, G719X) |
| Amivantamab IV and lazertinib 240 mg orally
|
Efficacy
|
ORR: 52% (95% CI, 42 to 62) |
| ORR in treatment-naive pts: 57% |
| mPFS: 11.1 mos (95% CI, 7.8 to 17.8) |
| mPFS in treatment-naive: 19.5 mos
|
Safety
|
Grade >=3 AE: Hypoalbuminemia (8%), rash (13%), paronychia (5%), |
| Serious AEs were reported in 53 (50%) participants |
| Any grade infusion-related reactions: 56% |
| 7% discontinued treatment due to AEs
|
J Clin Oncol Published online December 1, 2025.
http://doi.org/10.1200/JCO-24-02835
Reviewed by Ulas D. Bayraktar, MD on Dec 8, 2025
